Scholarlink

Purpose <p>Diabetes (DM) and hyperglycemia during chemotherapy increase the risk of toxicity, yet the prevalence and patterns of hyperglycemia in early-stage breast cancer (ESBC) patients undergoing chemotherapy with concurrent dexamethasone remain poorly understood.</p> Methods <p>We conducted a prospective single-arm study using FreeStyle Libre Pro continuous glucose monitoring in patients with ESBC receiving chemotherapy from 12/2020–2/2022. Sensors measured interstitial glucose every 15&#xa0;min and were reapplied every 2–3&#xa0;weeks. Primary endpoints were (1) prevalence of hyperglycemia (≥ 1 reading ≥ 140&#xa0;mg/dL), and (2) for those with hyperglycemia, the proportion of time spent hyperglycemic. Secondary endpoints included baseline glucose tolerance by A1c, changes in glucose-related biomarkers, and changes in patient-reported neuropathy, quality of life, and fatigue. Analysis was stratified by baseline A1c (euglycemic &lt; 5.7%, prediabetes [pre-DM] 5.7–6.4%, diabetes [DM] ≥ 6.5%).</p> Results <p>Among 20 evaluable patients (median age: 60, BMI: 29.5&#xa0;kg/m<sup>2</sup>), common chemotherapy regimens included docetaxel/cyclophosphamide (25%), paclitaxel/trastuzumab (20%), paclitaxel then doxorubicin/cyclophosphamide (15%), docetaxel/carboplatin/trastuzumab/pertuzumab (15%), and cyclophosphamide/methotrexate/fluorouracil (15%). All patients received Dexamethasone. At baseline, 10 patients were euglycemic, 7 had pre-DM, and 3 had DM. All experienced hyperglycemia. Of 124,165 total glucose readings, 17% were ≥ 140&#xa0;mg/dL. By cohort, the proportion of time spent hyperglycemic was 3.9% (euglycemic), 10% (pre-DM), and 73.3% (DM) (p &lt; .0001). Mean glucose values were 95.5&#xa0;mg/dL (euglycemic), 104.5&#xa0;mg/dL (pre-DM), and 183.0&#xa0;mg/dL (DM) (p &lt; .0001).</p> Conclusion <p>All patients receiving chemotherapy for ESBC experienced hyperglycemia, with time spent hyperglycemic varying significantly by baseline A1c. Future research should explore approaches to and benefits of improving glycemic control during treatment in patients with baseline dysglycemia.</p> <p>Trial registration: NCT04473378</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer

  • 期刊论文

  • 发表日期：

    2025年6月4日

查看全文
  • Sophie R. Ulene,
  • Shikun Wang,
  • Joshua R. Cook,
  • Fiona McAuley,
  • Margaux E. Wooster,
  • Khadija F. Faheem,
  • Andrew Varoli,
  • Julia E. McGuinness,
  • Neil Vasan,
  • Meghna S. Trivedi,
  • Katherine D. Crew,
  • Erik Harden,
  • Cynthia Law,
  • Dawn L. Hershman,
  • Melissa K. Accordino

摘要

Purpose

Diabetes (DM) and hyperglycemia during chemotherapy increase the risk of toxicity, yet the prevalence and patterns of hyperglycemia in early-stage breast cancer (ESBC) patients undergoing chemotherapy with concurrent dexamethasone remain poorly understood.

Methods

We conducted a prospective single-arm study using FreeStyle Libre Pro continuous glucose monitoring in patients with ESBC receiving chemotherapy from 12/2020–2/2022. Sensors measured interstitial glucose every 15 min and were reapplied every 2–3 weeks. Primary endpoints were (1) prevalence of hyperglycemia (≥ 1 reading ≥ 140 mg/dL), and (2) for those with hyperglycemia, the proportion of time spent hyperglycemic. Secondary endpoints included baseline glucose tolerance by A1c, changes in glucose-related biomarkers, and changes in patient-reported neuropathy, quality of life, and fatigue. Analysis was stratified by baseline A1c (euglycemic < 5.7%, prediabetes [pre-DM] 5.7–6.4%, diabetes [DM] ≥ 6.5%).

Results

Among 20 evaluable patients (median age: 60, BMI: 29.5 kg/m2), common chemotherapy regimens included docetaxel/cyclophosphamide (25%), paclitaxel/trastuzumab (20%), paclitaxel then doxorubicin/cyclophosphamide (15%), docetaxel/carboplatin/trastuzumab/pertuzumab (15%), and cyclophosphamide/methotrexate/fluorouracil (15%). All patients received Dexamethasone. At baseline, 10 patients were euglycemic, 7 had pre-DM, and 3 had DM. All experienced hyperglycemia. Of 124,165 total glucose readings, 17% were ≥ 140 mg/dL. By cohort, the proportion of time spent hyperglycemic was 3.9% (euglycemic), 10% (pre-DM), and 73.3% (DM) (p < .0001). Mean glucose values were 95.5 mg/dL (euglycemic), 104.5 mg/dL (pre-DM), and 183.0 mg/dL (DM) (p < .0001).

Conclusion

All patients receiving chemotherapy for ESBC experienced hyperglycemia, with time spent hyperglycemic varying significantly by baseline A1c. Future research should explore approaches to and benefits of improving glycemic control during treatment in patients with baseline dysglycemia.

Trial registration: NCT04473378